<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446039</url>
  </required_header>
  <id_info>
    <org_study_id>B2061147</org_study_id>
    <secondary_id>CAR-BIG Study</secondary_id>
    <nct_id>NCT04446039</nct_id>
  </id_info>
  <brief_title>Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea</brief_title>
  <official_title>Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate medication utilization pattern and risk
      of adverse outcomes among commonly used antidepressants by using nationwide claims database,
      in order to assess overall clinical benefit of antidepressant therapy in real-world practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While there are many antidepressants from which physicians can select based on efficacy and
      tolerability profile, evidence on effectiveness and safety outcomes of new antidepressants in
      real clinical practice among Korean MDD population is limited.

      Hence, this study will explore the following primary, secondary objectives using national
      health insurance database :

        1. Explore baseline characteristics and drug utilization patterns of 11 commonly used
           antidepressant therapy during 90 days of acute treatment phase

        2. Explore drug utilization patterns such as therapy changes, medication compliance and
           recurrence relationship, and risk of adverse outcomes during maintenance phase

        3. Choice of antidepressants and drug utilization patterns in patients with various
           comorbidities

        4. The relationship of non-pharmacologic treatment and discontinuation, medication
           compliance

        5. Choice of antidepressants by non-psychiatric specialty
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of antidepressants</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion out of total prescriptions in the first 90 days from the index date (acute treatment phase) by gender, age groups (20, 21-64, 65)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosage: Index date</measure>
    <time_frame>90 days</time_frame>
    <description>Initial dosages at the index date</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosage: Acute treatment phase</measure>
    <time_frame>90 days</time_frame>
    <description>Average dosages during the first 90 days of treatment (acute treatment phase)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence: Average length of treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Average length of treatment of each index drugs (allowing 14 day permissible gap) will be calculated.
-Switching, combination, augmentation, discontinuation will terminate the persistent period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuation</measure>
    <time_frame>90 days</time_frame>
    <description>Percentage of patients discontinued each index drug within first 90 days of index treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence</measure>
    <time_frame>90 days</time_frame>
    <description>For each index drug, adherence will be measured as percentage of drug possessed (measured by medication possession ratio) within 90 days of index treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients experiencing recurrence (as measured by inpatient episode, emergency room visit, or suicide attempt) within 6 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of adverse events (as measured by GI bleeding, fractures, falls, intracranial hemorrhage, suicide attempt, self-harm, myocardial infarction, epilepsy/seizures, stroke, hyponatremia) within 6 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug utilization pattern in acute phase</measure>
    <time_frame>90 days</time_frame>
    <description>Percentage of patients on monotherapy, combination therapy, augmentation therapy during 90 days of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug utilization pattern in maintenance phase</measure>
    <time_frame>90 days</time_frame>
    <description>Precentage of patients on monotherapy, combination therapy, augmentation therapy during 90-180 days of treatment</description>
  </secondary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>1. Escitalopram Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Paroxetine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Fluoxetine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Mirtazapine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>5. Duloxetine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>6. Sertraline Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>7. Venlafaxine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>8. Tianeptine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>9. Vortioxetine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>10. Desvenlafaxine Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>11. Bupropion Cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>1. Escitalopram Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>2. Paroxetine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>3. Fluoxetine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>4. Mirtazapine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>5. Duloxetine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>6. Sertraline Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>7. Venlafaxine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tianeptine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>8. Tianeptine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>9. Vortioxetine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>10. Desvenlafaxine Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Treatment for depression</description>
    <arm_group_label>11. Bupropion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who newly initiated antidepressant therapies between Jan 01, 2017 to Jun 30, 2018
        in the National Health Insurance Service (NHIS) database
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must meet all of the following inclusion criteria to be eligible for inclusion in
        the study:

          1. Patients aged 18 years or older on the index date

          2. Patients who had at least one inpatient claim or two outpatient claims in the intake
             period with any of the following diagnosis codes F06.3 Organic mood [affective]
             disorders F32* Depressive episode F33* Recurrent depressive disorder F34.1 Neurotic
             depression F38.1 Other recurrent mood [affective] disorder F41.2 Mixed anxiety and
             depressive disorder

          3. Patients prescribed any of the following antidepressant during intake period (from
             January 1, 2017 to June 30, 2018)

        Exclusion Criteria

        Patients meeting any of the following criteria will not be included in the study:

          1. Patients with a claim of diagnosis codes in Table 1 during the 12 month pre-index
             period

          2. Patients with a claim of prescription in Table 2 during the 12 month pre-index period

          3. Patient who had a claim as a beneficiary of Medical Aid program (Korean Medicaid
             program with free or minimum copay)

          4. Patients who are hospitalized at the index date

          5. Patients who are under hospice care (procedure codes WG*-WO*)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Vortioxetine</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
    <mesh_term>Tianeptine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

